Abstract: HJ Science, an autoimmune, metabolic and oncology drug developer, launched its Hong Kong IPO to raise USD143m. In this note, we look at the deal terms and recap our valuation thoughts for the company. We also look at the main reason that caps the return of the deal.
B&K CORP LTD -H, LBC HK
Interested in the full report? Get in touch with our team.